HC Wainwright Cuts BioXcel Therapeutics (NASDAQ:BTAI) Price Target to $5.00

BioXcel Therapeutics (NASDAQ:BTAI) had its target price decreased by HC Wainwright from $6.00 to $5.00 in a research report report published on Thursday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q1 2027 earnings at ($0.31) EPS, Q2 2027 earnings at ($0.29) EPS, Q3 2027 earnings at ($0.26) EPS and Q4 2027 earnings at ($0.26) EPS.

BTAI has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a report on Wednesday, January 21st. Zacks Research raised shares of BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, March 9th. Rodman & Renshaw assumed coverage on shares of BioXcel Therapeutics in a research report on Tuesday, March 17th. They issued a “buy” rating and a $17.00 target price for the company. Finally, Wall Street Zen upgraded shares of BioXcel Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $11.00.

BioXcel Therapeutics Stock Performance

Shares of BioXcel Therapeutics stock opened at $1.18 on Thursday. The stock has a market capitalization of $31.95 million, a price-to-earnings ratio of -0.18 and a beta of 0.30. BioXcel Therapeutics has a twelve month low of $1.08 and a twelve month high of $8.08. The business’s 50 day simple moving average is $1.54 and its 200-day simple moving average is $1.90.

BioXcel Therapeutics (NASDAQ:BTAI) last posted its earnings results on Friday, March 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.58). The company had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.15 million. Sell-side analysts predict that BioXcel Therapeutics will post -24.39 earnings per share for the current year.

Institutional Investors Weigh In On BioXcel Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of BTAI. Millennium Management LLC acquired a new stake in BioXcel Therapeutics in the third quarter worth about $2,632,000. Oaktree Capital Management LP acquired a new position in BioXcel Therapeutics during the 2nd quarter valued at about $437,000. Jane Street Group LLC acquired a new position in BioXcel Therapeutics during the 4th quarter valued at about $204,000. Geode Capital Management LLC raised its position in shares of BioXcel Therapeutics by 64.6% during the 4th quarter. Geode Capital Management LLC now owns 206,168 shares of the company’s stock worth $330,000 after buying an additional 80,928 shares in the last quarter. Finally, Man Group plc bought a new stake in shares of BioXcel Therapeutics during the 4th quarter worth about $91,000. 30.68% of the stock is currently owned by institutional investors.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.